This paper appears in the following:
- DC: Biomarkers, Parkinson’s—CAMD Needs All Hands on Deck
- Detecting Familial AD Ever Earlier: Subtle Memory Signs 15 Years Before
- Revised Diagnostic Criteria for Alzheimer’s Are Published
- London: What, No Argument? Speakers Agree on Trials for Familial AD
- Researchers Join to Draw Posterior Cortical Atrophy Out of Shadows
- The EMA Deems Brain Atrophy Valid Trial Selection Measure
- Will Technology Revolutionize Dementia Diagnosis and Care?
- Miami: Is Human Amyloid Imaging Ready for Clinical Trials?
- Clinical Trials: Task Force Supports Earlier Intervention
- Paris: Beyond Genomics, French Science Draws on Populations, Patients
- Is Structural MRI Closing In on Preclinical AD Biomarker?
- Safe at 4 Grams? No ARIA at High Dose of Human Aβ Antibody
- Are New Cognitive Tests Ready For Preclinical Trials?